keyword
MENU ▼
Read by QxMD icon Read
search

PDOX

keyword
https://www.readbyqxmd.com/read/30309504/tumor-targeting-salmonella-typhimurium-a1-r-overcomes-partial-carboplatinum-resistance-of-a-cancer-of-unknown-primary-cup
#1
Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, Ming Zhao, Sintawat Wangsiricharoen, Kei Kawaguchi, Zhiying Zhang, Takashi Higuchi, Sahar Razmjooei, Yunfeng Li, Scott D Nelson, Tara Russell, Arun Singh, Takashi Murakami, Yukihiko Hiroshima, Masashi Momiyama, Ryusei Matsuyama, Takashi Chishima, Shree Ram Singh, Sant P Chawla, Fritz C Eilber, Itaru Endo, Robert M Hoffman
Cancer of unknown primary (CUP) is metastatic disease without a known primary and therefore very difficult to identify effective therapy. Previously, we demonstrated partial efficacy of Salmonella typhimurium A1-R (S. typhimurium A1-R) alone and carboplatinum alone (CAR) on a CUP patient tumor in the patient-derived xenograft (PDOX) model. The aim of the present study was to investigate the efficacy of S. typhimurium A1-R combined with CAR on the CUP PDOX model. The CUP tumors were implanted orthotopically into the left supraclavicular fossa of nude mice to match the site from which they were resected from the patient...
October 2018: Tissue & Cell
https://www.readbyqxmd.com/read/30292411/a-combination-of-irinotecan-cisplatinum-and-irinotecan-temozolomide-or-tumor-targeting-salmonella-typhimurium-a1-r-arrest-doxorubicin-and-temozolomide-resistant-myxofibrosarcoma-in-a-pdox-mouse-model
#2
Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kentaro Miyake, Kentaro Igarashi, Kei Kawaguchi, Hiromichi Oshiro, Takashi Higuchi, Masuyo Miyake, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Bartosz Chmielowski, Scott D Nelson, Tara A Russell, Sarah M Dry, Yunfeng Li, Mark A Eckardt, Arun S Singh, Sant Chawla, Fuminori Kanaya, Fritz C Eilber, Shree Ram Singh, Ming Zhao, Robert M Hoffman
Myxofibrosarcoma (MFS) is the most common sarcomas in elderly patients and is either chemo-resistant or recurs with metastasis after chemotherapy. This recalcitrant cancer in need of improved treatment. We have established a patient-derived orthotopic xenograft (PDOX) of MFS. The MFS PDOX model was established in the biceps femoris of nude mice and randomized into 7 groups of 7 mice each: control; doxorubicin (DOX); pazopanib (PAZ); temozolomide (TEM); Irinotecan (IRN); IRN combined with TEM; IRN combined with cisplatinum (CDDP) and Salmonella typhimurium A1-R (S...
October 3, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/30275182/oral-recombinant-methioninase-combined-with-caffeine-and-doxorubicin-induced-regression-of-a-doxorubicin-resistant-synovial-sarcoma-in-a-pdox-mouse-model
#3
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, Qinghong Han, Yuying Tan, Hiromichi Oshiro, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Sant P Chawla, Arun S Singh, Frederick C Eilber, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M Hoffman
BACKGROUND/AIM: Synovial sarcoma (SS) is a recalcitrant neoplasm with low chemosensitivity. We recently reported that recombinant methioninase (rMETase) inhibited SS growth in a patient-derived orthotopic xenograft (PDOX) mouse model and was more effective when administered in combination with the first-line drug doxorubicin (DOX). Caffeine enhances the efficacy of anticancer drugs by overcoming drug-induced cell-cycle arrest and increasing subsequent apoptosis. Here, we determined the efficacy of oral recombinant methioninase (o-rMETase) in combined with caffeine on an SS-PDOX model...
October 2018: Anticancer Research
https://www.readbyqxmd.com/read/30166061/combination-therapy-of-tumor-targeting-salmonella-typhimurium-a1-r-and-oral-recombinant-methioninase-regresses-a-braf-v600e-negative-melanoma
#4
Kei Kawaguchi, Takashi Higuchi, Shukuan Li, Qinghong Han, Yuying Tan, Kentaro Igarashi, Ming Zhao, Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, Hiromichi Ohshiro, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Bartosz Chmielowski, Scott D Nelson, Tara A Russell, Sarah M Dry, Yunfeng Li, Mark A Eckardt, Arun S Singh, Shree Ram Singh, Fritz C Eilber, Michiaki Unno, Robert M Hoffman
Melanoma is a recalcitrant cancer. To improve and individualize treatment for this disease, we previously developed a patient-derived orthotopic xenograft (PDOX) model for melanoma. We previously reported the individual efficacy of tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) and recombinant methioninase (rMETase) for melanoma in the PDOX models of this disease. In the present study, we evaluated the efficacy of the combination of S. typhimurium A1-R with orally-administered rMETase (o-rMETase) for BRAF-V600E-negative melanoma in a PDOX model...
September 18, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/30126369/trabectedin-arrests-a-doxorubicin-resistant-pdgfra-activated-liposarcoma-patient-derived-orthotopic-xenograft-pdox-nude-mouse-model
#5
Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kei Kawaguchi, Kentaro Igarashi, Kentaro Miyake, Masuyo Miyake, Yunfeng Li, Scott D Nelson, Sarah M Dry, Arun S Singh, Tara A Russell, Irmina Elliott, Shree Ram Singh, Fuminori Kanaya, Fritz C Eilber, Robert M Hoffman
BACKGROUND: Pleomorphic liposarcoma (PLPS) is a rare, heterogeneous and an aggressive variant of liposarcoma. Therefore, individualized therapy is urgently needed. Our recent reports suggest that trabectedin (TRAB) is effective against several patient-derived orthotopic xenograft (PDOX) mouse models. Here, we compared the efficacy of first-line therapy, doxorubicin (DOX), and TRAB in a platelet-derived growth factor receptor-α (PDGFRA)-amplified PLPS. METHODS: We used a fresh sample of PLPS tumor derived from a 68-year-old male patient diagnosed with a recurrent PLPS...
August 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30080930/advantages-of-patient-derived-orthotopic-mouse-models-and-genetic-reporters-for-developing-fluorescence-guided-surgery
#6
REVIEW
Thinzar M Lwin, Robert M Hoffman, Michael Bouvet
Fluorescence-guided surgery can enhance the surgeon's ability to achieve a complete oncologic resection. There are a number of tumor-specific probes being developed with many preclinical mouse models to evaluate their efficacy. The current review discusses the different preclinical mouse models in the setting of probe evaluation and highlights the advantages of patient-derived orthotopic xenografts (PDOX) mouse models and genetic reporters to develop fluorescence-guided surgery.
August 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/30073742/ph-reduction-dual-triggered-degradable-poly-doxorubicin-prodrug-nanoparticles-for-leakage-free-tumor-specific-self-delivery
#7
Jiagen Li, Peng Liu
Poly(doxorubicin) (PDOX) is synthesized with Mn of 1.66 × 104 and DOX content of 78% as prodrug for tumor-specific triggered release, via a facile condensation polymerization of DOX-SS-DOX and adipic dihydrazide. The PDOX nanoparticles (PDOX-NPs) could completely release DOX-SH within 1.5 days at the simulated tumor microenvironment, but no measurable leakage in the physiological media. The in vitro controlled release results show that the releasing rate is influenced by the dosage and independent of the particle size, while the solubility of the degraded products should be the main determining factor for the drug release from the PDOX-NPs...
September 2018: Macromolecular Rapid Communications
https://www.readbyqxmd.com/read/30060824/doxorubicin-resistant-pleomorphic-liposarcoma-with-pdgfra-gene-amplification-is-targeted-and-regressed-by-pazopanib-in-a-patient-derived-orthotopic-xenograft-mouse-model
#8
Tasuku Kiyuna, Takashi Murakami, Yasunori Tome, Kentaro Igarashi, Kei Kawaguchi, Kentaro Miyake, Masuyo Miyake, Yunfeng Li, Scott D Nelson, Sarah M Dry, Arun S Singh, Tara A Russell, Shree Ram Singh, Fuminori Kanaya, Fritz C Eilber, Robert M Hoffman
Pleomorphic liposarcoma (PLPS) is a heterogeneous resistant group of tumors. Complete surgical resection is the only known way to treat PLPS. PLPS is reristant to both radiation and chemotherapy. Therefore, precise individualized therapy is needed to improve outcome of advanced PLPS patients. In this study, a patient-derived orthotopic xenograft (PDOX) model of a PDGFRA-amplified PLPS was established in the biceps femoris of nude mice by surgical orthotopic implantation (SOI) in order to match the patient. The PLPS PDOX was treated with pazopanib (PAZ) which targets PDGFRA, as well as with temozolomide (TEM) and first-line therapy doxorubicin (DOX)...
August 2018: Tissue & Cell
https://www.readbyqxmd.com/read/30055076/partially-oxidized-palladium-nanodots-for-enhanced-electrocatalytic-carbon-dioxide-reduction
#9
Hui Lu, Le Zhang, Ju Hua Zhong, Hua Gui Yang
Here we report a partially oxidized palladium nanodot (Pd/PdOx ) catalyst with a diameter of around 4.5 nm. In aqueous CO2 -saturated 0.5 m KHCO3 , the catalyst displays a Faradaic efficiency (FE) of 90 % at -0.55 V vs. reversible hydrogen electrode (RHE) for carbon monoxide (CO) production, and the activity can be retained for at least 24 h. The improved catalytic activity can be attributed to the strong adsorption of CO2 .- intermediate on the Pd/PdOx electrode, wherein the presence of Pd2+ during the electroreduction reaction of CO2 may play an important role in accelerating the carbon dioxide reduction reaction (CO2 RR)...
October 4, 2018: Chemistry, An Asian Journal
https://www.readbyqxmd.com/read/30024282/patterns-of-sensitivity-to-a-panel-of-drugs-are-highly-individualised-for-undifferentiated-unclassified-soft-tissue-sarcoma-usts-in-patient-derived-orthotopic-xenograft-pdox-nude-mouse-models
#10
Kei Kawaguchi, Kentaro Igarashi, Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, Arun S Singh, Bartosz Chmielowski, Scott D Nelson, Tara A Russell, Sarah M Dry, Yunfeng Li, Michiaki Unno, Shree Ram Singh, Fritz C Eilber, Robert M Hoffman
Undifferentiated/unclassified soft tissue sarcoma (USTS) is a recalcitrant disease; therefore, precise individualised therapy is needed. Toward this goal, we previously established patient-derived orthotopic xenograft (PDOX) models of USTS in nude mice. Here, we determined the extent of uniqueness of drug response in a panel on USTS PDOX models from 5 different patients. We previously showed that 3 of the 5 patients were resistant to doxorubicin (DOX) despite DOX being first-line therapy. Two weeks after orthotopic tumour implantation, PDOX mouse models were randomised into five groups: untreated control, DOX, gem-citabine/docetaxel (GEM/DOC), pazopanib (PAZ), temozolomide (TEM)...
August 23, 2018: Journal of Drug Targeting
https://www.readbyqxmd.com/read/30003151/tumor-targeting-salmonella-typhimurium-a1-r-suppressed-an-imatinib-resistant-gastrointestinal-stromal-tumor-with-c-kit-exon-11-and-17-mutations
#11
Kentaro Miyake, Kei Kawaguchi, Masuyo Miyake, Ming Zhao, Tasuku Kiyuna, Kentaro Igarashi, Zhiying Zhang, Takashi Murakami, Yunfeng Li, Scott D Nelson, Michael Bouvet, Irmina Elliott, Tara A Russell, Arun S Singh, Yukihiko Hiroshima, Masashi Momiyama, Ryusei Matsuyama, Takashi Chishima, Shree Ram Singh, Itaru Endo, Fritz C Eilber, Robert M Hoffman
Gastrointestinal stromal tumor (GIST) is a refractory disease in need of novel efficacious therapy. The aim of our study was to evaluate the effectiveness of tumor-targeting Salmonella typhimurium A1-R ( S. typhimurium A1-R) using on a patient derived orthotopic xenograft (PDOX) model of imatinib-resistant GIST. The GIST was obtained from a patient with regional recurrence, and implanted in the anterior gastric wall of nude mice. The GIST PDOX mice were randomized into 3 groups of 6 mice each when the tumor volume reached 60 mm3 : G1, control group; G2, imatinib group (oral administration [p...
June 2018: Heliyon
https://www.readbyqxmd.com/read/29963961/tumor-targeting-salmonella-typhimurium-a1-r-in-combination-with-gemcitabine-gem-regresses-partially-gem-resistant-pancreatic-cancer-patient-derived-orthotopic-xenograft-pdox-nude-mouse-models
#12
Kei Kawaguchi, Kentaro Miyake, Ming Zhao, Tasuku Kiyuna, Kentaro Igarashi, Masuyo Miyake, Takashi Higuchi, Hiromichi Oshiro, Michael Bouvet, Michiaki Unno, Robert M Hoffman
Gemcitabine (GEM) is first-line therapy for pancreatic cancer but has limited efficacy in most cases. Nanoparticle-albumin bound (nab)-paclitaxel is becoming first-line therapy for pancreatic cancer, but also has limited efficacy for pancreatic cancer. Our goal was to improve the treatment outcome in patient-like models of pancreatic cancer. We previously established patient-derived orthotopic xenografts (PDOX) pancreatic cancers from two patients. The pancreatic tumor was implanted orthotopically in the pancreatic tail of nude mice to establish the PDOX models...
2018: Cell Cycle
https://www.readbyqxmd.com/read/29932244/tumor-targeting-salmonella-typhimurium-a1-r-arrests-a-doxorubicin-resistant-pdgfra-amplified-patient-derived-orthotopic-xenograft-mouse-model-of-pleomorphic-liposarcoma
#13
Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Ming Zhao, Kentaro Miyake, Kentaro Igarashi, Kei Kawaguchi, Masuyo Miyake, Hiromichi Oshiro, Takashi Higuchi, Yunfeng Li, Sarah M Dry, Scott D Nelson, Tara A Russell, Mark A Eckardt, Arun S Singh, Fuminori Kanaya, Fritz C Eilber, Robert M Hoffman
Pleomorphic liposarcoma (PLPS) is a recalcitrant soft-tissue sarcoma (STS) subtype in need of transformative therapy. We have previously established a patient-derived orthotopic xenograft (PDOX) model, of PLPS with PDGFRA amplification, using surgical orthotopic implantation. In the current study, the PLPS PDOX model was randomized into 3 groups of 7 mice each: untreated control; doxorubicin (DOX)-treated; and treated with Salmonella typhimurium A1-R (S. typhimurium A1-R) expressing green fluorescent protein (GFP)...
September 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29928962/oral-recombinant-methioninase-o-rmetase-is-superior-to-injectable-rmetase-and-overcomes-acquired-gemcitabine-resistance-in-pancreatic-cancer
#14
Kei Kawaguchi, Kentaro Miyake, Qinghong Han, Shukuan Li, Yuying Tan, Kentaro Igarashi, Tasuku Kiyuna, Masuyo Miyake, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Michael Bouvet, Shree Ram Singh, Michiaki Unno, Robert M Hoffman
Recombinant methioninase (rMETase) was previously administered as an injectable drug to target methionine dependence of cancer. Recently, we observed that rMETase could be administered orally (o-rMETase) in a patient-derived orthotopic xenograft (PDOX) mouse model of melanoma. Here, we determined the efficacy of o-rMETase on a pancreatic cancer PDOX model. Forty pancreatic cancer PDOX mouse models were randomized into four groups of 10 mice each. o-rMETase was significantly more effective than i.p.-rMETase, but the combination of both was significantly more effective than either alone...
September 28, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29924472/outstanding-methane-oxidation-performance-of-palladium-embedded-ceria-catalysts-prepared-by-a-one-step-dry-ball-milling-method
#15
Maila Danielis, Sara Colussi, Carla de Leitenburg, Lluís Soler, Jordi Llorca, Alessandro Trovarelli
By carefully mixing Pd metal nanoparticles with CeO2 polycrystalline powder under dry conditions, an unpredicted arrangement of the Pd-O-Ce interface is obtained in which an amorphous shell containing palladium species dissolved in ceria is covering a core of CeO2 particles. The robust contact that is generated at the nanoscale, along with mechanical forces generated during mixing, promotes the redox exchange between Pd and CeO2 and creates highly reactive and stable sites constituted by PdOx embedded into CeO2 surface layers...
August 6, 2018: Angewandte Chemie
https://www.readbyqxmd.com/read/29892358/selective-and-metal-free-epoxidation-of-terminal-alkenes-by-heterogeneous-polydioxirane-in-mild-conditions
#16
M Kazemnejadi, A Shakeri, M Nikookar, R Shademani, M Mohammadi
Polydioxirane (PDOX) was prepared by the treatment of polysalicylaldehyde with Oxone and was found as a selective, highly efficient and heterogeneous reagent for epoxidation of alkenes which can be successfully isolated. This work also introduced a simpler, safer and milder way for epoxidation of alkenes with dioxirane groups than before. PDOX can be simply recovered from the reaction mixture by plain filtration and reused for eight runs without significant reactivity loss.
May 2018: Royal Society Open Science
https://www.readbyqxmd.com/read/29857821/mek-inhibitor-trametinib-in-combination-with-gemcitabine-regresses-a-patient-derived-orthotopic-xenograft-pdox-pancreatic-cancer-nude-mouse-model
#17
Kei Kawaguchi, Kentaro Igarashi, Kentaro Miyake, Thinzar M Lwin, Masuyo Miyake, Tasuku Kiyuna, Ho Kyoung Hwang, Takashi Murakami, Jonathan C Delong, Shree Ram Singh, Bryan Clary, Michael Bouvet, Michiaki Unno, Robert M Hoffman
Pancreatic cancer is resistant to treatment and needs precision individualized therapy to improve the outcome of this disease. Previously, we demonstrated that trametinib (TRA), a MEK inhibitor, could inhibit a pancreatic cancer patient-derived orthotopic xenograft (PDOX). In the present study, we show that gemcitabine (GEM) in combination with TRA was more effective than TRA alone. We implanted a patient pancreatic cancer orthotopically in the pancreatic tail of nude mice to establish the PDOX model. After seven weeks of tumor growth, we divided 32 pancreatic-cancer PDOX nude mice into 4 groups of eight: untreated control; GEM (once a week for 2 weeks); TRA (14 consecutive days); GEM + TRA (GEM: once a week for 2 weeks, TRA:14 consecutive days)...
June 2018: Tissue & Cell
https://www.readbyqxmd.com/read/29737543/temozolomide-regresses-a-doxorubicin-resistant-undifferentiated-spindle-cell-sarcoma-patient-derived-orthotopic-xenograft-pdox-precision-oncology-nude-mouse-model-matching-the-patient-with-effective-therapy
#18
Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, Kentaro Miyake, Masuyo Miyake, Yunfeng Li, Scott D Nelson, Sarah M Dry, Arun S Singh, Irmina A Elliott, Tara A Russell, Mark A Eckardt, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Hiroyuki Tsuchiya, Fritz C Eilber, Robert M Hoffman
Undifferentiated spindle-cell sarcoma (USCS) is a recalcitrant cancer, resistant to conventional chemotherapy. A patient with high-grade USCS from a striated muscle was implanted orthotopically in the right biceps femoris muscle of mice to establish a patient-derived orthotopic xenograft (PDOX) model. The PDOX models were randomized into the following groups when tumor volume reached 100 mm3 : G1, control without treatment; G2, doxorubicin (DOX) (3 mg/kg, intraperitoneal [i.p.] injection, weekly, for 2 weeks); G3, temozolomide (TEM) (25 mg/kg, p...
August 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29721200/recombinant-methioninase-combined-with-doxorubicin-dox-regresses-a-dox-resistant-synovial-sarcoma-in-a-patient-derived-orthotopic-xenograft-pdox-mouse-model
#19
Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, Qinghong Han, Yuying Tan, Emily Gainor, Tasuku Kiyuna, Kentaro Miyake, Masuyo Miyake, Takashi Higuchi, Hiromichi Oshiro, Arun S Singh, Mark A Eckardt, Scott D Nelson, Tara A Russell, Sarah M Dry, Yunfeng Li, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Hiroyuki Tsuchiya, Fritz C Eilber, Robert M Hoffman
Synovial sarcoma (SS) is a recalcitrant subgroup of soft tissue sarcoma (STS). A tumor from a patient with high grade SS from a lower extremity was grown orthotopically in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) mouse model. The PDOX mice were randomized into the following groups when tumor volume reached approximately 100 mm3 : G1, control without treatment; G2, doxorubicin (DOX) (3 mg/kg, intraperitoneal [i.p.] injection, weekly, for 2 weeks; G3, rMETase (100 unit/mouse, i...
April 10, 2018: Oncotarget
https://www.readbyqxmd.com/read/29713497/patient-derived-orthotopic-xenograft-models-for-cancer-of-unknown-primary-precisely-distinguish-chemotherapy-and-tumor-targeting-s-typhimurium-a1-r-is-superior-to-first-line-chemotherapy
#20
Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, Kei Kawaguchi, Sang Nam Yoon, Zhiying Zhang, Kentaro Igarashi, Sahar Razmjooei, Sintawat Wangsiricharoen, Takashi Murakami, Yunfeng Li, Scott D Nelson, Tara A Russell, Arun S Singh, Yukihiko Hiroshima, Masashi Momiyama, Ryusei Matsuyama, Takashi Chishima, Shree Ram Singh, Itaru Endo, Fritz C Eilber, Robert M Hoffman
Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of S. typhimurium A1-R with first-line chemotherapy using the CUP PDOX model...
2018: Signal Transduction and Targeted Therapy
keyword
keyword
159915
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"